The state of New Mexico urged a judge to hold Walgreens Boots Alliance Inc responsible for fueling the opioid crisis in the state.
Dan Alberstone, a lawyer for New Mexico, told Judge Francis Matthew in the 1st Judicial Circuit of New Mexico in Santa Fe, that the opioid crisis existing in New Mexico was a foreseeable consequence of Walgreens' conduct."
Alberstone accused the company of failing to "maintain effective controls" against the diversion of opioids onto the black market, saying it dispensed suspicious prescriptions without adequate due diligence or documentation.
Steven Derringer, the lawyer arguing for Walgreens, insisted that the opioid crisis was caused by excessive prescriptions and smaller, "mom and pop" pharmacies with lax controls. He added that the state had not offered any evidence that Walgreens dispensed any prescriptions without "legitimate medical purpose."
When the non-jury trial began six weeks ago, it also included claims against Walmart Inc and Kroger Co, but those companies settled with the state last month.


Sara Duterte Posts Bail Over Grave Threats Case
Dollar Falls as Oil Eases, Yen Jumps on Intervention Signals
Airbus Finds A321neo Fuselage Quality Issue
Japanese Yen Rebounds as Trump Flags Currency Weakness
Venezuela Nears Deal to Move $4 Billion in Gold to New York Fed
Erste Group Plans Tender Offer to Boost Poland Bank Stake
Paramount-Warner Bros $110 Billion Deal Draws Antitrust Backlash
US Appeals Court Upholds Anthropic AI Supply Chain Ban
Trump Asks Supreme Court to Restore Third-Country Deportations
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
Asian Currencies Mixed as Dollar Holds Near Two-Month High
Trump, Xi Focus on Trade and AI at White House Summit
Suzuki Targets Faster Car Development to Keep Pace With Chinese Rivals
US Court Approves airBaltic Chapter 11 Restructuring
FDA Approves Mirum’s Atebrioz for Rare Bone Disorder FOP
Judge Orders Trump to Restore White House Access for CNN, MS NOW and Politico
Almonty Industries Shares Jump 8% After Stifel Sets $25 Target 



